Bench 2 Breakthrough Podcast Episode 3 - Lets talk all things Statistics

Clinical development is complex. The path is uncertain. And every decision matters — especially the statistical ones.

🎙Episode 3 of Accelagen's Bench 2 Breakthrough Podcast, we bring statistics out of the back room and into the real-world conversations that determine whether trials stay on track. We are joined by Rebecca Asher, Accelagen's Head of Biostatistics where she shares her insights on the importance of statistics input early in the development pathway and how this can benefit the outcome

🎯 We explore how statistical planning, data strategy, and operational decision-making work together to deliver outcomes sponsors can stand behind — not just faster, but more predictably. We focus on the choices that strengthen trial credibility: anticipating variability, setting realistic endpoints and assumptions, building analysis readiness, and ensuring data is structured to stand up under scrutiny.

📰 In the wrap of recent news, we discuss how the geopolitical events in the Middle East are impacting clinical trial execution, and also review the recently issued report entitled 'Ambitious Australia' that discusses the strategic overhaul of Australia's research, development, and innovation (RD&I) system to lift productivity and boost economic resilience

🎧 Click here to listen to the episode: https://www.youtube.com/watch?v=iTXGIKXacrA

‍We love your feedback and if you have any questions from this episode, let us know and we will cover in future episode.

‍